Using topical imiquimod for the management of positive in situ margins after XXXX resection.

@entity75 @entity1 @entity320
UNASSIGNED: The treatment of @entity320 in situ (MIS) is controversial with current standard of care being surgical excision with clear margins. Alternative topical therapy with imiquimod has been proposed in recent studies as a possible treatment for MIS. This study aimed to evaluate the use of topical 5% imiquimod as an alternative approach for the treatment of @entity320 in situ after surgical resection of the @entity75 . A retrospective chart review of all @entity1 treated with topical 5% imiquimod for residual MIS following standard resection with 5-10  mm margins at Yale-New Haven Hospital from 2008 through 2013 was performed. The pre- and posttreatment results were confirmed by diagnostic tissue biopsy. Twenty-two @entity1 were included in the study. One of these 22 @entity1 was lost to follow up. Twenty @entity1 (95%) had complete resolution of their residual MIS and 1 @entity1 did not respond to imiquimod (5%). No reports of recurrences were noted at the treatment sites. For @entity1 with @entity320 in situ after the initial excision, topical 5% imiquimod appears to be a reasonable alternative treatment with good clinical and histopathologic success rates.
